Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1994 Jun;144(6):1135–1141.

Death at Sverdlovsk: what have we learned?

D H Walker 1, O Yampolska 1, L M Grinberg 1
PMCID: PMC1887476  PMID: 8203454

Full text

PDF
1135

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBRINK W. S., BROOKS S. M., BIRON R. E., KOPEL M. Human inhalation anthrax. A report of three fatal cases. Am J Pathol. 1960 Apr;36:457–471. [PMC free article] [PubMed] [Google Scholar]
  2. ALBRINK W. S., GOODLOW R. J. Experimental inhalation anthrax in the chimpanzee. Am J Pathol. 1959 Sep-Oct;35:1055–1065. [PMC free article] [PubMed] [Google Scholar]
  3. Abramova A. A., Grinberg L. M. Patologicheskaia anatomiia sibireiazvennogo sepsisa po materialam infektsionnoi vspyshki 1979g v Sverdlovske (mikroskopicheskie izmeneniia). Arkh Patol. 1993 Jan-Feb;55(1):18–23. [PubMed] [Google Scholar]
  4. Abramova A. A., Grinberg L. M. Patologicheskaia anatomiia sibireiazvennogo sepsisa po materialam infektsionnoi vspyshki 1979g. v Sverdlovske (makroskopicheskie izmeneniia). Arkh Patol. 1993 Jan-Feb;55(1):12–17. [PubMed] [Google Scholar]
  5. Abramova F. A., Grinberg L. M., Yampolskaya O. V., Walker D. H. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2291–2294. doi: 10.1073/pnas.90.6.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Arora N., Leppla S. H. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem. 1993 Feb 15;268(5):3334–3341. [PubMed] [Google Scholar]
  7. BEALL F. A., TAYLOR M. J., THORNE C. B. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol. 1962 Jun;83:1274–1280. doi: 10.1128/jb.83.6.1274-1280.1962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. BERDJIS C. C., GOCHENOUR W. S., Jr, HENDERSON J. E. MODIFICATION OF ANTHRAX BY IONIZING RADIATION. J Infect Dis. 1963 Nov-Dec;113:219–227. doi: 10.1093/infdis/113.3.219. [DOI] [PubMed] [Google Scholar]
  9. Bhatnagar R., Singh Y., Leppla S. H., Friedlander A. M. Calcium is required for the expression of anthrax lethal toxin activity in the macrophagelike cell line J774A.1. Infect Immun. 1989 Jul;57(7):2107–2114. doi: 10.1128/iai.57.7.2107-2114.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Blaustein R. O., Koehler T. M., Collier R. J., Finkelstein A. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2209–2213. doi: 10.1073/pnas.86.7.2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brachman P. S. Inhalation anthrax. Ann N Y Acad Sci. 1980;353:83–93. doi: 10.1111/j.1749-6632.1980.tb18910.x. [DOI] [PubMed] [Google Scholar]
  12. Brachman P. S., Kaufman A. F., Dalldorf F. G. Industrial inhalation Anthrax. Bacteriol Rev. 1966 Sep;30(3):646–659. doi: 10.1128/br.30.3.646-659.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. DRUETT H. A., HENDERSON D. W., PACKMAN L., PEACOCK S. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond) 1953 Sep;51(3):359–371. doi: 10.1017/s0022172400015795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dalldorf F. G., Kaufmann A. F., Brachman P. S. Woolsorters' disease. An experimental model. Arch Pathol. 1971 Dec;92(6):418–426. [PubMed] [Google Scholar]
  15. Dickson D. Gene splicing dominates review of weapons pact. Science. 1986 Oct 10;234(4773):143–145. doi: 10.1126/science.2875523. [DOI] [PubMed] [Google Scholar]
  16. Doğanay M., Almaç A., Hanağasi R. Primary throat anthrax. A report of six cases. Scand J Infect Dis. 1986;18(5):415–419. doi: 10.3109/00365548609032357. [DOI] [PubMed] [Google Scholar]
  17. Dutz W., Kohout E. Anthrax. Pathol Annu. 1971;6:209–248. [PubMed] [Google Scholar]
  18. Escuyer V., Collier R. J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect Immun. 1991 Oct;59(10):3381–3386. doi: 10.1128/iai.59.10.3381-3386.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ezzell J. W., Jr, Abshire T. G. Serum protease cleavage of Bacillus anthracis protective antigen. J Gen Microbiol. 1992 Mar;138(3):543–549. doi: 10.1099/00221287-138-3-543. [DOI] [PubMed] [Google Scholar]
  20. Fish D. C., Mahlandt B. G., Dobbs J. P., Lincoln R. E. Purification and properties of in vitro-produced anthrax toxin components. J Bacteriol. 1968 Mar;95(3):907–918. doi: 10.1128/jb.95.3.907-918.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Friedlander A. M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986 Jun 5;261(16):7123–7126. [PubMed] [Google Scholar]
  22. Friedlander A. M., Welkos S. L., Pitt M. L., Ezzell J. W., Worsham P. L., Rose K. J., Ivins B. E., Lowe J. R., Howe G. B., Mikesell P. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993 May;167(5):1239–1243. doi: 10.1093/infdis/167.5.1239. [DOI] [PubMed] [Google Scholar]
  23. GLEISER C. A., BERDJIS C. C., HARTMAN H. A., GOCHENOUR W. S. PATHOLOGY OF EXPERIMENTAL RESPIRATORY ANTHRAX IN MACACA MULATTA. Br J Exp Pathol. 1963 Aug;44:416–426. [PMC free article] [PubMed] [Google Scholar]
  24. GOCHENOUR W. S., Jr, SAWYER W. D., HENDERSON J. E., GLEISER C. A., KUEHNE R. W., TIGERTT W. D. ON THE RECOGNITION AND THERAPY OF SIMIAN WOOLSORTER'S DISEASE. J Hyg (Lond) 1963 Sep;61:317–322. doi: 10.1017/s0022172400039590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. GOLD H. Anthrax; a report of one hundred seventeen cases. AMA Arch Intern Med. 1955 Sep;96(3):387–396. doi: 10.1001/archinte.1955.00250140109012. [DOI] [PubMed] [Google Scholar]
  26. Grinberg L. M., Abramova A. A. Patologicheskaia anatomiia sibireiazvennogo sepsisa po materialam infektsionnoi vspyshki 1979 g. v Sverdlovske (nekotorye voprotsy morfo-, pato- i tanatogeneza. Arkh Patol. 1993 Jan-Feb;55(1):23–26. [PubMed] [Google Scholar]
  27. HENDERSON D. W., PEACOCK S., BELTON F. C. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956 Mar;54(1):28–36. doi: 10.1017/s0022172400044272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Hambleton P., Carman J. A., Melling J. Anthrax: the disease in relation to vaccines. Vaccine. 1984 Jun;2(2):125–132. doi: 10.1016/0264-410x(84)90003-3. [DOI] [PubMed] [Google Scholar]
  29. Hanna P. C., Acosta D., Collier R. J. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10198–10201. doi: 10.1073/pnas.90.21.10198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci. 1992 Dec 31;666:21–52. doi: 10.1111/j.1749-6632.1992.tb38021.x. [DOI] [PubMed] [Google Scholar]
  31. Ivins B. E., Welkos S. L. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol. 1988 Mar;4(1):12–19. doi: 10.1007/BF00152686. [DOI] [PubMed] [Google Scholar]
  32. Jena G. P. Intestinal anthrax in man: a case report. Cent Afr J Med. 1980 Dec;26(12):253–254. [PubMed] [Google Scholar]
  33. KLEIN F., HODGES D. R., MAHLANDT B. G., JONES W. I., HAINES B. W., LINCOLN R. E. Anthrax toxin: causative agent in the death of rhesus monkeys. Science. 1962 Dec 21;138(3547):1331–1333. doi: 10.1126/science.138.3547.1331. [DOI] [PubMed] [Google Scholar]
  34. Klimpel K. R., Molloy S. S., Thomas G., Leppla S. H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10277–10281. doi: 10.1073/pnas.89.21.10277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. LaForce F. M., Bumford F. H., Feeley J. C., Stokes S. L., Snow D. B. Epidemiologic study of a fatal case of inhalation anthrax. Arch Environ Health. 1969 May;18(5):798–805. doi: 10.1080/00039896.1969.10665490. [DOI] [PubMed] [Google Scholar]
  36. Labruyère E., Mock M., Surewicz W. K., Mantsch H. H., Rose T., Munier H., Sarfati R. S., Bârzu O. Structural and ligand-binding properties of a truncated form of Bacillus anthracis adenylate cyclase and of a catalytically inactive variant in which glutamine substitutes for lysine-346. Biochemistry. 1991 Mar 12;30(10):2619–2624. doi: 10.1021/bi00224a008. [DOI] [PubMed] [Google Scholar]
  37. Laforce F. M. Woolsorters' disease in England. Bull N Y Acad Med. 1978 Nov;54(10):956–963. [PMC free article] [PubMed] [Google Scholar]
  38. Leppla S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982 May;79(10):3162–3166. doi: 10.1073/pnas.79.10.3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Leppla S. H. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;17:189–198. [PubMed] [Google Scholar]
  40. Lincoln R. E., Hodges D. R., Klein F., Mahlandt B. G., Jones W. I., Jr, Haines B. W., Rhian M. A., Walker J. S. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis. 1965 Dec;115(5):481–494. doi: 10.1093/infdis/115.5.481. [DOI] [PubMed] [Google Scholar]
  41. Little S. F., Lowe J. R. Location of receptor-binding region of protective antigen from Bacillus anthracis. Biochem Biophys Res Commun. 1991 Oct 31;180(2):531–537. doi: 10.1016/s0006-291x(05)81097-6. [DOI] [PubMed] [Google Scholar]
  42. Mikesell P., Ivins B. E., Ristroph J. D., Dreier T. M. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 1983 Jan;39(1):371–376. doi: 10.1128/iai.39.1.371-376.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Mock M., Labruyère E., Glaser P., Danchin A., Ullmann A. Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli. Gene. 1988 Apr 29;64(2):277–284. doi: 10.1016/0378-1119(88)90342-3. [DOI] [PubMed] [Google Scholar]
  44. Nalin D. R., Sultana B., Sahunja R., Islam A. K., Rahim M. A., Islam M., Costa B. S., Mawla N., Greenough W. B., 3rd Survival of a patient with intestinal anthrax. Am J Med. 1977 Jan;62(1):130–132. doi: 10.1016/0002-9343(77)90358-8. [DOI] [PubMed] [Google Scholar]
  45. Novak J. M., Stein M. P., Little S. F., Leppla S. H., Friedlander A. M. Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem. 1992 Aug 25;267(24):17186–17193. [PubMed] [Google Scholar]
  46. PLOTKIN S. A., BRACHMAN P. S., UTELL M., BUMFORD F. H., ATCHISON M. M. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med. 1960 Dec;29:992–1001. doi: 10.1016/0002-9343(60)90079-6. [DOI] [PubMed] [Google Scholar]
  47. Parvizpour D. Human anthrax in Iran: an epidemiological study of 468 cases. Int J Zoonoses. 1978 Dec;5(2):69–74. [PubMed] [Google Scholar]
  48. Pezard C., Berche P., Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect Immun. 1991 Oct;59(10):3472–3477. doi: 10.1128/iai.59.10.3472-3477.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Poupard J. A., Miller L. A. History of biological warfare: catapults to capsomeres. Ann N Y Acad Sci. 1992 Dec 31;666:9–20. doi: 10.1111/j.1749-6632.1992.tb38020.x. [DOI] [PubMed] [Google Scholar]
  50. Quinn C. P., Singh Y., Klimpel K. R., Leppla S. H. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J Biol Chem. 1991 Oct 25;266(30):20124–20130. [PubMed] [Google Scholar]
  51. Robertson D. L., Tippetts M. T., Leppla S. H. Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene. 1988 Dec 20;73(2):363–371. doi: 10.1016/0378-1119(88)90501-x. [DOI] [PubMed] [Google Scholar]
  52. SMITH H., KEPPIE J., STANLEY J. L. Observations on the cause of death in experimental anthrax. Lancet. 1954 Sep 4;267(6836):474–476. doi: 10.1016/s0140-6736(54)91881-4. [DOI] [PubMed] [Google Scholar]
  53. STANLEY J. L., SARGEANT K., SMITH H. Purification of factors I and II of the anthrax toxin produced in vivo. J Gen Microbiol. 1960 Feb;22:206–218. doi: 10.1099/00221287-22-1-206. [DOI] [PubMed] [Google Scholar]
  54. STANLEY J. L., SMITH H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol. 1961 Sep;26:49–63. doi: 10.1099/00221287-26-1-49. [DOI] [PubMed] [Google Scholar]
  55. Severn M. A fatal case of pulmonary anthrax. Br Med J. 1976 Mar 27;1(6012):748–748. doi: 10.1136/bmj.1.6012.748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Singh Y., Chaudhary V. K., Leppla S. H. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem. 1989 Nov 15;264(32):19103–19107. [PubMed] [Google Scholar]
  57. Singh Y., Klimpel K. R., Quinn C. P., Chaudhary V. K., Leppla S. H. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J Biol Chem. 1991 Aug 15;266(23):15493–15497. [PubMed] [Google Scholar]
  58. Suffin S. C., Carnes W. H., Kaufmann A. F. Inhalation anthrax in a home craftsman. Hum Pathol. 1978 Sep;9(5):594–597. doi: 10.1016/s0046-8177(78)80140-3. [DOI] [PubMed] [Google Scholar]
  59. Taylor J. P., Dimmitt D. C., Ezzell J. W., Whitford H. Indigenous human cutaneous anthrax in Texas. South Med J. 1993 Jan;86(1):1–4. doi: 10.1097/00007611-199301000-00001. [DOI] [PubMed] [Google Scholar]
  60. Tippetts M. T., Robertson D. L. Molecular cloning and expression of the Bacillus anthracis edema factor toxin gene: a calmodulin-dependent adenylate cyclase. J Bacteriol. 1988 May;170(5):2263–2266. doi: 10.1128/jb.170.5.2263-2266.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Turnbull P. C., Broster M. G., Carman J. A., Manchee R. J., Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun. 1986 May;52(2):356–363. doi: 10.1128/iai.52.2.356-363.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Turnbull P. C., Leppla S. H., Broster M. G., Quinn C. P., Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol. 1988;177(5):293–303. doi: 10.1007/BF00189414. [DOI] [PubMed] [Google Scholar]
  63. Uchida I., Sekizaki T., Hashimoto K., Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol. 1985 Feb;131(2):363–367. doi: 10.1099/00221287-131-2-363. [DOI] [PubMed] [Google Scholar]
  64. Vodkin M. H., Leppla S. H. Cloning of the protective antigen gene of Bacillus anthracis. Cell. 1983 Sep;34(2):693–697. doi: 10.1016/0092-8674(83)90402-6. [DOI] [PubMed] [Google Scholar]
  65. Wade N. Death at Sverdlovsk: a critical diagnosis. Science. 1980 Sep 26;209(4464):1501–1502. doi: 10.1126/science.7433972. [DOI] [PubMed] [Google Scholar]
  66. Walker J. S., Lincoln R. E., Klein F. Pathophysiological and biochemical changes in anthrax. Fed Proc. 1967 Sep;26(5):1539–1544. doi: 10.21236/ad0811760. [DOI] [PubMed] [Google Scholar]
  67. Welkos S. L. Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb Pathog. 1991 Mar;10(3):183–198. doi: 10.1016/0882-4010(91)90053-d. [DOI] [PubMed] [Google Scholar]
  68. Xia Z. G., Storm D. R. A-type ATP binding consensus sequences are critical for the catalytic activity of the calmodulin-sensitive adenylyl cyclase from Bacillus anthracis. J Biol Chem. 1990 Apr 25;265(12):6517–6520. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES